Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara; Sarah Paul; Marcin Kowanetz; Erica Schleifman; Wei Zou; Yan Li; Achim Rittmeyer; Louis Fehrenbacher; Geoff Otto; Christine M. Malboeuf; Daniel S. Lieber; Doron Lipson; Jacob Silterra; Lukas C. Amler; Todd Riehl; Craig Cummings; Priti S. Hegde; Alan Sandler; Marcus Ballinger; David Fabrizio; Tony Mok; David S. Shames

doi:10.1038/s41591-018-0134-3

Keywords

AtezolizumabMedicineLung cancerOncologyInternal medicineImmunotherapyBiomarkerLiquid biopsyCancerPembrolizumab

Affiliated Institutions

Related Publications

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi , Matthew D. Hellmann , Alexandra Snyder +21 more

Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this...

2015 Science 7740 citations

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann , Tudor‐Eliade Ciuleanu , Adam Płużański +21 more

Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden,...

2018 New England Journal of Medicine 3061 citations

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann , Tavi Nathanson , Hira Rizvi +29 more

Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequen...

2018 Cancer Cell 1147 citations

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Timothy A. Chan , Mark Yarchoan , Elizabeth M. Jaffee +4 more

Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...

2018 Annals of Oncology 2769 citations

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch , Marileila Varella‐Garcia , Paul A. Bunn +16 more

Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cance...

2006 Journal of Clinical Oncology 702 citations

Publication Info

Year: 2018
Type: article
Volume: 24
Issue: 9
Pages: 1441-1448
Citations: 1160
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1160

OpenAlex

Cite This

APA Style

                            
                                
                                    David R. Gandara, 
                                
                                    Sarah Paul, 
                                
                                    Marcin Kowanetz
                                
                                et al.
                            
                            (2018). 
                            Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. 
                            Nature Medicine
                            , 24
                            (9)
                            , 1441-1448.
                            https://doi.org/10.1038/s41591-018-0134-3
                        

Identifiers

DOI: 10.1038/s41591-018-0134-3